Question 1

What is the difference between Cortexin and Cerebrolysin?

Accepted Answer

Both are brain-derived neuropeptide complexes used for neurological conditions, but they differ in several important ways. Cortexin is derived from bovine (calf) cerebral cortex and is administered intramuscularly in 10 mg doses. Cerebrolysin is derived from porcine (pig) brain and can be given intravenously in much larger volumes (up to 50 mL). Cerebrolysin has larger international clinical trials (including the CASTA stroke trial with 1,070 patients) and is approved in over 40 countries. Cortexin's clinical data is predominantly Russian, and it is primarily available in Russia and CIS countries. Their peptide compositions differ due to species of origin and extraction methods.

Question 2

Is Cortexin available in the United States or Europe?

Accepted Answer

Cortexin is not FDA-approved and is not available through conventional pharmacies in the United States or EU countries. It is registered as a pharmaceutical product in Russia and several CIS countries. Western access is limited to research-grade suppliers and international pharmacies. No regulatory submission has been made to the FDA, EMA, or MHRA.

Question 3

Is Cortexin safe given that it is derived from animal brain tissue?

Accepted Answer

Cortexin is produced through acid extraction and enzymatic processing that reduces proteins to low-molecular-weight peptides under 10 kDa — well below the size threshold for prion proteins or intact viral particles. The manufacturing process includes purification steps designed to eliminate transmissible agents. It has been used clinically in Russia since 1999 with millions of patient-treatments and no reported cases of prion or viral transmission. However, Western regulatory agencies have not independently reviewed the manufacturing safety data, and some neurologists outside Russia remain cautious about any bovine brain-derived product given historical BSE concerns.

Question 4

What conditions is Cortexin used for in Russia?

Accepted Answer

In Russian clinical practice, Cortexin is used for a broad range of neurological conditions: acute and chronic cerebrovascular disease (stroke recovery), traumatic brain injury, cognitive decline in elderly patients, epilepsy as adjunct therapy, neurodevelopmental delays in children (including perinatal CNS damage), and encephalopathy of various origins. It is classified as both a nootropic and neuroprotector in Russian pharmacological classification. The breadth of approved indications reflects the Russian regulatory approach to multi-component biological preparations.

Question 5

How is Cortexin administered?

Accepted Answer

Cortexin is supplied as a lyophilized powder in vials (5 mg or 10 mg) and must be reconstituted before injection. It is administered exclusively by intramuscular injection, typically into the deltoid or gluteal muscle. The standard reconstitution uses 1–2 mL of 0.5% procaine (novocaine) solution or 0.9% sodium chloride. Unlike Cerebrolysin, Cortexin cannot be given intravenously. Injections are given once daily, and the reconstituted solution should be used immediately — it cannot be stored.

Question 6

Does Cortexin actually improve cognitive function?

Accepted Answer

Russian clinical studies report improvements in cognitive test scores (memory, attention, executive function) in elderly patients with vascular cognitive impairment and in children with neurodevelopmental delays after 10-day Cortexin courses. However, these studies have methodological limitations by Western standards — many are open-label, use small sample sizes, and lack placebo controls. No double-blind, placebo-controlled RCT of Cortexin has been published in an international peer-reviewed journal. The cognitive benefits reported in Russian literature are plausible given the neurotrophic mechanism but await independent confirmation.

Question 7

Can Cortexin be used for children?

Accepted Answer

Yes, Cortexin is widely used in Russian pediatric neurology. It is approved for children including infants for conditions such as perinatal CNS damage, neurodevelopmental delays, speech disorders, and epilepsy. Pediatric dosing is weight-based: 5 mg for children under 20 kg, 10 mg for those over 20 kg, administered IM once daily for 10-day courses. Russian pediatric literature reports favorable outcomes, but these studies have not been replicated in Western clinical settings and no international pediatric guidelines include Cortexin.

Question 8

How does Cortexin compare to synthetic nootropic peptides like Semax?

Accepted Answer

Cortexin is a multi-component biological preparation containing hundreds of peptide fragments, while Semax is a single synthetic heptapeptide (ACTH 4-10 analog) with a well-defined amino acid sequence. Semax has a clearer pharmacological profile — it primarily upregulates BDNF and modulates monoamine neurotransmission. Cortexin acts through multiple undefined pathways simultaneously. Semax is administered intranasally (more convenient); Cortexin requires intramuscular injection. Both are products of Russian neuropharmacology and both lack Western regulatory approval. Some Russian neurologists combine them for complementary neurotrophic coverage.

Question 9

What is the relationship between Cortexin and Cortagen?

Accepted Answer

Cortagen (AEDG) is a synthetic tetrapeptide developed by Khavinson's group at the Saint Petersburg Institute of Bioregulation and Gerontology as the minimal active peptide fragment from the Cortexin complex. While Cortexin contains hundreds of peptide fragments from bovine cortex tissue, Cortagen is a single defined four-amino-acid sequence proposed to replicate the core regulatory activity. Cortagen is oral/sublingual; Cortexin is injectable. Cortagen has less clinical data than Cortexin but offers standardization advantages.

Question 10

What are the side effects of Cortexin?

Accepted Answer

Published Russian pharmacovigilance data reports a favorable safety profile. The most common adverse effect is pain or discomfort at the injection site, which is mitigated by reconstitution with procaine solution. Allergic reactions (skin rash, urticaria) are reported rarely. No serious adverse events, organ toxicity, or drug dependency have been reported in published literature. Contraindications listed in the Russian prescribing information include known hypersensitivity to the preparation and pregnancy (due to insufficient safety data). Post-marketing surveillance data covers millions of patient-treatments since 1999.

Question 11

How long does it take for Cortexin to work?

Accepted Answer

Clinical improvement timelines vary by indication. In acute stroke protocols, neurological improvements on the NIHSS scale are typically observed by day 5–7 of a 10-day course. For cognitive enhancement in elderly patients, improvements on neuropsychological testing are usually measured at the end of the 10-day course and at follow-up. Some Russian clinicians report that maximal cognitive benefits become apparent 2–4 weeks after completing a course, as downstream neurotrophic effects (BDNF upregulation, synaptic remodeling) continue beyond the treatment period. Repeat courses are standard practice for sustained benefit.

Origin / Manufacturer	Bovine cerebral cortex-derived
Active Components	Neuropeptide complex (low-molecular-weight, ≤10 kDa)Free amino acids (glycine stabilizer base)Water-soluble vitamins (trace amounts)Minerals (trace amounts)
Storage	Store at 2–8°C, protect from light
Shelf Life	36 months
Form Factor	Lyophilized powder for IM injection (5 mg and 10 mg vials)

Cortexin

Specifications

Clinical Evidence

Frequently Asked Questions

Sources & References

Related Peptides

Cerebrolysin

Cortagen

Dihexa

Pinealon

Selank

Semax